NYSE$AMN
AMN Healthcare Services Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
AMN Healthcare reported a decrease in revenue and net income compared to the previous year, but exceeded adjusted EBITDA margin guidance due to operating leverage.
AMN Healthcare announced its fourth quarter and full year 2022 financial results. The company's Q4 revenue was $1.126 billion, a 17% decrease over prior year. Net income was $82 million, or $1.88 per diluted share, compared with $116 million, or $2.42 per diluted share, in the same quarter last year. Adjusted diluted EPS was $2.48 compared with $2.95 in the year-ago quarter.
- Consolidated revenue for the quarter was $1.126 billion, a 17% decrease over prior year.
- Net income was $82 million (7.3% of revenue), or $1.88 per diluted share.
- Adjusted diluted EPS was $2.48 compared with $2.95 in the year-ago quarter.
- Revenue for the Nurse and Allied Solutions segment was $825 million, flat sequentially and lower by 24% year over year.
Headline financials
Revenue & EPS history
AMN Healthcare · Revenue · Quarterly
$1.13B
Revenue by segment
AMN Healthcare · $1.13B total across 3 segments · Q4 2022
- Nurse & Allied Solutions$825M-23.7%73.3%
- Physician & Leadership$168M+2.6%14.9%
- Technology & Workforce$133M+13.3%11.8%
Forward guidance
Consolidated revenue in the first quarter of 2023 is projected to be 27-29% lower than the record-high revenue of the year-ago period.
Tailwinds
- Gross margin is expected to be higher by approximately 90 basis points year over year, driven by an improved Nurse and Allied margin
- Gross margin is expected to be higher by approximately 90 basis points year over year, driven by a revenue mix shift toward our higher-margin businesses.
- Nurse and Allied Solutions segment revenue is expected to be flat sequentially
- Guidance assumes an immaterial amount of labor disruption revenue in the quarter.
- Stock repurchase authorization.
Headwinds
- Consolidated revenue in the first quarter of 2023 is projected to be 27-29% lower than the record-high revenue of the year-ago period.
- Nurse and Allied Solutions segment revenue is expected to be 32-34% below prior year.
- Physician and Leadership Solutions segment revenue in the first quarter to be down 10-12% year over year.
- Technology and Workforce Solutions segment revenue also is expected to be down 10-12% year over year.
- Normalizing trend in staffing demand and bill rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.0%
Avg return
Earnings day
-1.9%
Avg return
5 days after
-0.6%
Avg return
30 days after
52%
34 / 66 earnings
Positive
+29.2%
Q1 2026
Best reaction
-29.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +29.2% | +38.5% | +41.5% | |
| Q4 2025 | +11.4% | +15.8% | +4.2% | |
| Q3 2025 | -3.4% | -10.0% | -11.8% | |
| Q2 2025 | +2.3% | +10.2% | +23.2% | |
| Q1 2025 | +8.2% | +7.1% | +3.8% | |
| Q4 2024 | +6.7% | +0.5% | -6.8% | |
| Q3 2024 | -29.5% | -36.7% | -36.2% | |
| Q2 2024 | -3.1% | -11.9% | -24.0% | |
| Q1 2024 | -9.3% | +3.4% | -10.1% | |
| Q4 2023 | -20.9% | -25.5% | -24.7% | |
| Q3 2023 | -12.2% | -17.7% | -9.5% | |
| Q2 2023 | -16.4% | -16.6% | -18.6% | |
| Q1 2023 | +7.7% | +10.3% | +18.0% | |
| Q4 2022 | -4.0% | -2.3% | -13.4% | |
| Q3 2022 | -7.5% | -0.4% | +1.7% | |
| Q2 2022 | +1.8% | -1.7% | -12.7% | |
| Q1 2022 | -8.2% | -10.6% | -1.3% | |
| Q4 2021 | +8.8% | +5.3% | +10.4% | |
| Q3 2021 | -8.2% | -1.4% | +3.7% | |
| Q2 2021 | +5.4% | +3.8% | +15.4% | |
| Q1 2021 | +7.6% | +10.3% | +11.0% | |
| Q4 2020 | +4.1% | -0.7% | +1.4% | |
| Q3 2020 | -5.8% | -7.0% | -1.9% | |
| Q2 2020 | +4.8% | -4.5% | -1.7% | |
| Q1 2020 | -9.3% | -12.1% | +13.0% | |
| Q4 2019 | +9.6% | +5.6% | +4.0% | |
| Q3 2019 | -0.5% | +2.1% | +0.8% | |
| Q2 2019 | +7.7% | +11.4% | +15.5% | |
| Q1 2019 | +1.9% | -0.4% | -6.0% | |
| Q4 2018 | -12.5% | -14.7% | -26.7% | |
| Q3 2018 | +13.3% | +11.6% | +23.9% | |
| Q2 2018 | -15.2% | -10.4% | -5.4% | |
| Q1 2018 | -21.9% | -21.6% | -14.6% | |
| Q4 2017 | +4.8% | +4.8% | +10.9% | |
| Q3 2017 | -3.6% | -1.6% | +16.3% | |
| Q2 2017 | +1.1% | +6.9% | +4.4% | |
| Q1 2017 | -6.8% | -6.2% | -9.0% | |
| Q4 2016 | +4.0% | +7.9% | +10.3% | |
| Q3 2016 | -1.6% | -2.7% | -7.8% | |
| Q2 2016 | -11.9% | -13.8% | -13.5% | |
| Q1 2016 | +1.0% | — | — | |
| Q4 2015 | +1.8% | — | — | |
| Q3 2015 | +5.9% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +5.7% | — | — | |
| Q1 2014 | +3.8% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q4 2012 | +13.4% | — | — | |
| Q3 2013 | +13.4% | — | — | |
| Q2 2013 | +6.1% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q3 2012 | +4.0% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q1 2011 | +19.4% | — | — | |
| Q1 2012 | +6.1% | — | — | |
| Q4 2011 | -2.0% | — | — | |
| Q4 2009 | -2.0% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q1 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro